共 73 条
[1]
Jemal A(2011)Global cancer statistics CA Cancer J Clin. 61 69-90
[2]
Bray F(2010)Prostate Cancer Working Group report Jpn J Clin Oncol. 40 i70-i75
[3]
Center MM(2011)Epidemiology of prostate cancer in Japan Nihon Rinsyo. 69 181-186
[4]
Ferlay J(2010)The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival Eur J Cancer. 46 517-525
[5]
Ward E(1988)Strontium-89 therapy: measurement of absorbed dose to skeletal metastases J Nucl Med. 29 549-557
[6]
Forman D(2001)Strontium-89 treatment for prostate cancer bone metastases: does a prostate-specific antigen response predict for improved survival? Australas Radiol. 45 39-42
[7]
Namiki M(2010)The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival Eur J Cancer. 46 517-525
[8]
Akaza H(2010)Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 1147-1154
[9]
Lee SE(2012)Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med. 367 1187-1197
[10]
Song JM(1993)Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer Int J Radiat Oncol Biol Phys. 25 805-813